Highlights Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-13 pm EDT			5-day change	1st Jan Change
53.52 ^USD	-0.91%		-2.46%	-4.75%

Jun. 04	Exact Sciences Corporation, Q1 2025 Earnings Call, May 01, 2025
Jun. 03	Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08:40 AM

Highlights

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect? Test and Molecular Residual Disease Innovation Roadmap	May. 28	CI
Exact Sciences Corp. Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025	May. 22	CI
US FDA approves first at-home test for cervical cancer screening	May. 09	RE
Exact Sciences Q1 Adjusted Loss Narrows, Revenue Rises; Shares Up	May. 01	MT
Earnings Flash (EXAS) Exact Sciences Posts Q1 Loss $-0.21 Per Share, vs. FactSet Est of $-0.25	May. 01	MT
Earnings Flash (EXAS) Exact Sciences Posts Q1 Revenue $706.8M, vs. FactSet Est of $688.6M	May. 01	MT
Exact Sciences Corporation Revises Earnings Guidance for the Year 2025	May. 01	CI
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 01	CI
Exact Sciences Launches the Oncodetect Molecular Residual Disease Test	Apr. 22	CI
Exact Sciences Corp. Announces Publication of Comprehensive Review in JAMA Oncology That Strengthens the Evidence Supporting the Oncotype DX Breast Recurrence Score Test	Apr. 14	CI
Exact Sciences Corp. Launches the Cologuard Plus?? Test, Transforming Colorectal Cancer Screening	Mar. 31	CI
Exact Sciences Corporation Announces the Presentation of New Data Further Confirming the Utility of Its Oncotype Dx Breast Recurrence Score®? Test At the 19thst. Gallen International Breast Cancer Conference in Vienna, Austria	Mar. 12	CI
Exact Sciences Corporation Provides Earnings Guidance for the First Quarter of 2025	Feb. 19	CI
Exact Sciences Q4 Net Loss Widens, Revenue Up; Sets Outlook	Feb. 19	MT
Earnings Flash (EXAS) Exact Sciences Posts Q4 Revenue $713.4M, vs. FactSet Est of $701.9M	Feb. 19	MT
Earnings Flash (EXAS) Exact Sciences Reports Q4 Loss $-0.06 Per Share	Feb. 19	MT
Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Feb. 19	CI
Exact Sciences Corporation Provides Earnings Guidance for the Full Year of 2025	Feb. 19	CI
Barclays Initiates Exact Sciences at Overweight	Jan. 23	MT
Exact Sciences to Seek M&A	Jan. 13	CI
Exact Sciences Expects 10% Growth in Q4 Revenue	Jan. 13	MT
Exact Sciences Corp. and Lil Jon Partner on "Get Low #2" Campaign to Encourage Colon Cancer Screening	Dec. 02	CI
BTIG Raises Price Target on Exact Sciences to $75 From $65, Maintains Buy Rating	Nov. 26	MT
Exact Sciences Insider Bought Shares Worth $1,001,325, According to a Recent SEC Filing	Nov. 13	MT
Top Premarket Decliners	Nov. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Highlights

Filters